Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 13 Oral semaglutide has demonstrated a consistent reduction in HbA1c and body weight in the completed PIONEER trials In completed PIONEER trials, oral semaglutide lowered HbA1c by 1.1-1.8%-points by end of trial¹ Mean change in HbA1c (%-points) In completed PIONEER trials, oral semaglutide lowered body weight by ~2-5 kg by end of trial¹ Mean change in weight (kg) P4 P5 P7 P8 P10 P1 0.0% P2 P3 P4 P5 P7 P8 P10 P1 P2 P3 0.0 -1.0 -0.5% -2.0 -1.0% -3.0 -1.1%* -1.1%* -1.5% -1.3%* -1.2%* -1.2%* -4.0 -1.4%* -4.1* آاتا -3.5* -1.5%* -5.0 -4.7* -2.0% -1.8%* -6.0 !! -2.9* -3.7* -5.0* -4.3* -1.9* 1 Hypothetical estimand, Mixed Model for Repeated Measurement (MMRM) *Statistically significant vs comparator (vs placebo in PIONEER 1; vs empagliflozin 25 mg in PIONEER 2; vs sitagliptin 100 mg in PIONEER 3; vs Victoza® 1.8 mg in PIONEER 4; vs placebo in PIONEER 5; vs sitagliptin 100 mg in PIONEER 7; vs placebo in PIONEER 8; vs 0.75 mg dulaglutide in PIONEER 10) Note: Results shown are: PIONEER 1 and 5 for 26 weeks with 14 mg oral semaglutide, PIONEER 2, 4, 8 and 10 for 52 weeks with 14 mg oral semaglutide; PIONEER 3 for 78 weeks with 14 mg oral semaglutide; PIONEER 7 for 52 weeks with a mixed dose P: PIONEER novo nordisk

View entire presentation